These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 34030964)

  • 1. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
    Andronikou C; Rottenberg S
    Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
    Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
    Zhang L; Li DQ
    Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP1-modulated chromatin remodeling is a new target for cancer treatment.
    Sinha S; Molla S; Kundu CN
    Med Oncol; 2021 Aug; 38(10):118. PubMed ID: 34432161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PARP Way to Epigenetic Changes.
    Ummarino S; Hausman C; Di Ruscio A
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
    Kamaletdinova T; Fanaei-Kahrani Z; Wang ZQ
    Cells; 2019 Dec; 8(12):. PubMed ID: 31842403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer.
    Zhan Z; Zhang J; Liang H; Wang C; Hong L; Liu W
    Adv Sci (Weinh); 2024 Sep; 11(34):e2400140. PubMed ID: 38973255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
    Pettitt SJ; Krastev DB; Brandsma I; Dréan A; Song F; Aleksandrov R; Harrell MI; Menon M; Brough R; Campbell J; Frankum J; Ranes M; Pemberton HN; Rafiq R; Fenwick K; Swain A; Guettler S; Lee JM; Swisher EM; Stoynov S; Yusa K; Ashworth A; Lord CJ
    Nat Commun; 2018 May; 9(1):1849. PubMed ID: 29748565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication.
    Zhang H; Zha S
    DNA Repair (Amst); 2024 Aug; 140():103690. PubMed ID: 38823186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of PARP as a successful target for cancer therapy.
    Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
    Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.
    Chen HD; Chen CH; Wang YT; Guo N; Tian YN; Huan XJ; Song SS; He JX; Miao ZH
    Int J Cancer; 2019 Aug; 145(3):714-727. PubMed ID: 30675909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Poly-ADP-Ribose Trigger Releases the Auto-Inhibition of a Chromatin Remodeling Oncogene.
    Singh HR; Nardozza AP; Möller IR; Knobloch G; Kistemaker HAV; Hassler M; Harrer N; Blessing C; Eustermann S; Kotthoff C; Huet S; Mueller-Planitz F; Filippov DV; Timinszky G; Rand KD; Ladurner AG
    Mol Cell; 2017 Dec; 68(5):860-871.e7. PubMed ID: 29220653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
    Kanev PB; Atemin A; Stoynov S; Aleksandrov R
    Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
    Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.